Back

Conventional medical therapies in patients with heart failure across different risk for transthyretin amyloid cardiomyopathy in the DELIVER, PARAGON-HF and TOPCAT Americas trials

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pathophysiology and mechanisms 10 Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Riccardo Maria Inciardi

Civil Hospital of Brescia, Brescia (Italy)

7 More presentations in this session

Presentation thumbnail
True prevalence of transthyretin cardiac amyloidosis in an unselected heart failure with preserved ejection fraction cohort
Miss A. Achten (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
The value of scoring systems in terms of phenogroups in the diagnosis of heart failure with preserved ejection fraction
Associate Professor S. Murat (Eskisehir, TR)
Abstract Slides Video
Presentation thumbnail
Inter-atrial block as a predictor of adverse outcomes in patients with HFpEF
Miss S. Mourmans (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Association between N-terminal pro-brain natriuretic peptide and maximal functional capacity in heart failure with preserved ejection fraction: the modifying role of obesity
Doctor P. Palau Sampio (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
Associations of peroxiredoxin-4, a circulating antioxidant, with incident heart failure
Doctor N. Suthahar (Rotterdam, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - pathophysiology and mechanisms 10

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Cardiac resynchronization therapy, remodeling and outcome in patients with amyloid transthyretin cardiomyopathy
thumbnail
Congress Presentation
Amyloid-specific medication in transthyretin amyloid cardiomyopathy: a systemic review and meta-analysis.
thumbnail
Congress Presentation
Disease progression and outcomes in patients with transthyretin amyloid cardiomyopathy receiving tafamidis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources